{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:28:37Z","timestamp":1791430117764,"version":"4.3.3"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-026-05634-7","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:55:28Z","timestamp":1783173328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Artificial intelligence-enabled MRI surveillance of prostate cancer: integrating PRECISE v2, PI-QUAL, and longitudinal biomarkers\u2014a narrative review"],"prefix":"10.1007","author":[{"given":"Motohiro","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jina","family":"Pakpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdar","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve Nur","family":"Tasdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Roest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Purysko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"1","key":"5634_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JU.0000000000002758","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, et al (2022) Clinically localized prostate cancer: AUA\/ASTRO guideline, Part II: principles of active surveillance, principles of surgery, and follow-up. J Urol 208(1):19\u201325. doi:https:\/\/doi.org\/10.1097\/JU.0000000000002758","journal-title":"J Urol"},{"issue":"2","key":"5634_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, et al (2021) EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2):243\u2013262. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042","journal-title":"Eur Urol"},{"key":"5634_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrurol.2015.313","volume":"13","author":"SM Bruinsma","year":"2016","unstructured":"Bruinsma SM, Bangma CH, Carroll PR, et al (2016) Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol 13:151\u2013167. https:\/\/doi.org\/10.1038\/nrurol.2015.313","journal-title":"Nat Rev Urol"},{"key":"5634_CR4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, et al (2018) MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 378:1767\u20131777. https:\/\/doi.org\/10.1056\/NEJMoa1801993","journal-title":"N Engl J Med"},{"key":"5634_CR5","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815\u2013822. https:\/\/doi.org\/10.1016\/S0140-6736(16)32401-1","journal-title":"Lancet"},{"key":"5634_CR6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"M van der Leest","year":"2019","unstructured":"van der Leest M, Cornel E, Israel B, et al (2019) Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naive men with elevated prostate-specific antigen: a large prospective multicenter clinical study. Eur Urol 75:570\u2013578. https:\/\/doi.org\/10.1016\/j.eururo.2018.11.023","journal-title":"Eur Urol"},{"key":"5634_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","volume":"20","author":"O Rouvi\u00e8re","year":"2019","unstructured":"Rouvi\u00e8re O, Puech P, Renard-Penna R, et al (2019) Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 20:100\u2013109. https:\/\/doi.org\/10.1016\/S1470-2045(18)30569-2","journal-title":"Lancet Oncol"},{"issue":"1","key":"5634_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.21037\/tau.2017.12.23","volume":"7","author":"F Giganti","year":"2018","unstructured":"Giganti F, Moore CM (2018) Magnetic resonance imaging in active surveillance - a modern approach. Transl Androl Urol 7(1):116\u2013131. https:\/\/doi.org\/10.21037\/tau.2017.12.23","journal-title":"Transl Androl Urol"},{"issue":"5","key":"5634_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","volume":"80","author":"P Rajwa","year":"2021","unstructured":"Rajwa P, Pradere B, Quhal F, et al (2021) Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. Eur Urol 80(5):549\u2013563. https:\/\/doi.org\/10.1016\/j.eururo.2021.05.001","journal-title":"Eur Urol"},{"issue":"10","key":"5634_CR10","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1007\/s00330-020-06929-z","volume":"30","author":"M de Rooij","year":"2020","unstructured":"de Rooij M, Isra\u00ebl B, Tummers M, et al (2020) ESUR\/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists\u2019 training. Eur Radiol 30(10):5404\u20135416. https:\/\/doi.org\/10.1007\/s00330-020-06929-z","journal-title":"Eur Radiol"},{"issue":"4","key":"5634_CR11","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.eururo.2016.06.011","volume":"71","author":"CM Moore","year":"2017","unstructured":"Moore CM, Giganti F, Albertsen P, et al (2017) Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force. Eur Urol 71(4):648\u2013655. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.011","journal-title":"Eur Urol"},{"key":"5634_CR12","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3348\/jksr.2025.0076","volume":"86","author":"MJ Kim","year":"2025","unstructured":"Kim MJ, Kang KA, Kim CK (2025) Standardizing prostate MRI reporting in active surveillance for prostate cancer: the PRECISE framework. J Korean Soc Radiol 86:830\u2013846. https:\/\/doi.org\/10.3348\/jksr.2025.0076","journal-title":"J Korean Soc Radiol"},{"issue":"3","key":"5634_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.eururo.2024.03.014","volume":"86","author":"C Englman","year":"2024","unstructured":"Englman C, Maffei D, Allen C, et al (2024) PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer. Eur Urol 86(3):240\u2013255. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.014","journal-title":"Eur Urol"},{"issue":"5","key":"5634_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2214\/AJR.23.29518","volume":"221","author":"R Sanmugalingam","year":"2023","unstructured":"Sanmugalingam R, Sushentsev N, Lee G, et al (2023) The PRECISE Recommendations for Prostate MRI in Patients on Active Surveillance for Prostate Cancer: A Critical Review. AJR Am J Roentgenol 221(5):649\u2013660. https:\/\/doi.org\/10.2214\/AJR.23.29518","journal-title":"AJR Am J Roentgenol"},{"key":"5634_CR15","doi-asserted-by":"publisher","first-page":"9567","DOI":"10.1007\/s00330-021-08021-6","volume":"31","author":"T Penzkofer","year":"2021","unstructured":"Penzkofer T, Padhani AR, Turkbey B, et al (2021) ESUR\/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging. Eur Radiol 31:9567\u20139578. https:\/\/doi.org\/10.1007\/s00330-021-08021-6","journal-title":"Eur Radiol"},{"key":"5634_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/15353508251393056","volume":"24","author":"J Xu","year":"2025","unstructured":"Xu J, Gao C, Zhang J, et al (2025) Advancements in imaging technologies and AI integration for neurodegenerative disease management: a narrative review. Mol Imaging 24:1\u201317. https:\/\/doi.org\/10.1177\/15353508251393056","journal-title":"Mol Imaging"},{"issue":"3","key":"5634_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, et al (2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76(3):340\u2013351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033","journal-title":"Eur Urol"},{"issue":"4","key":"5634_CR18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2214\/AJR.20.23985","volume":"216","author":"F Giganti","year":"2021","unstructured":"Giganti F, Kirkham A, Allen C, et al (2021) Update on Multiparametric Prostate MRI During Active Surveillance: Current and Future Trends and Role of the PRECISE Recommendations. AJR Am J Roentgenol 216(4):943\u2013951. https:\/\/doi.org\/10.2214\/AJR.20.23985","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"5634_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.euo.2020.06.007","volume":"3","author":"F Giganti","year":"2020","unstructured":"Giganti F, Allen C, Emberton M, et al (2020) Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial. Eur Urol Oncol 3(5):615\u2013619. https:\/\/doi.org\/10.1016\/j.euo.2020.06.007","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"5634_CR20","doi-asserted-by":"publisher","first-page":"7068","DOI":"10.1007\/s00330-024-10795-4","volume":"34","author":"M de Rooij","year":"2024","unstructured":"de Rooij M, Allen C, Twilt JJ, et al (2024) PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI. Eur Radiol 34(11):7068\u20137079. https:\/\/doi.org\/10.1007\/s00330-024-10795-4","journal-title":"Eur Radiol"},{"issue":"13","key":"5634_CR21","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jama.2025.13722","volume":"334","author":"ABCD Ng","year":"2025","unstructured":"Ng ABCD, Asif A, Agarwal R, et al (2025) Biparametric vs multiparametric MRI for prostate cancer diagnosis: the PRIME diagnostic clinical trial. JAMA 334(13):1170\u20131179. https:\/\/doi.org\/10.1001\/jama.2025.13722","journal-title":"JAMA"},{"key":"5634_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13244-022-01252-1","volume":"13","author":"F Giganti","year":"2022","unstructured":"Giganti F, Aupin L, Thoumin C, et al (2022) Promoting the use of the PRECISE score for prostate MRI during active surveillance: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship. Insights Imaging 13:111. https:\/\/doi.org\/10.1186\/s13244-022-01252-1","journal-title":"Insights Imaging"},{"issue":"1","key":"5634_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00330-022-08947-5","volume":"33","author":"F Giganti","year":"2023","unstructured":"Giganti F, Cole AP, Fennessy FM, et al (2023) Promoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship. Eur Radiol 33(1):461\u2013471. https:\/\/doi.org\/10.1007\/s00330-022-08947-5","journal-title":"Eur Radiol"},{"issue":"17","key":"5634_CR24","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.3390\/cancers13174251","volume":"13","author":"C Manceau","year":"2021","unstructured":"Manceau C, Fromont G, Beauval J-B, et al. Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review. Cancers (Basel). 2021;13(17):4251. doi:https:\/\/doi.org\/10.3390\/cancers13174251","journal-title":"Cancers (Basel)"},{"issue":"6","key":"5634_CR25","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/cncr.29874","volume":"122","author":"CP Filson","year":"2016","unstructured":"Filson CP, Natarajan S, Margolis DJA, et al (2016) Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies. Cancer 122(6):884\u2013892. https:\/\/doi.org\/10.1002\/cncr.29874","journal-title":"Cancer"},{"issue":"1","key":"5634_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2214\/AJR.20.24268","volume":"216","author":"IG Schoots","year":"2021","unstructured":"Schoots IG, Barentsz JO, Bittencourt LK, et al (2021) PI-RADS committee position on MRI without contrast medium in biopsy-naive men with suspected prostate cancer: narrative review. AJR Am J Roentgenol 216(1):3\u201319. https:\/\/doi.org\/10.2214\/AJR.20.24268","journal-title":"AJR Am J Roentgenol"},{"key":"5634_CR27","unstructured":"European Association of Urology (EAU) (2026) EAU Guidelines on Prostate Cancer. Chapter: Treatment (Section 6.2.1.c Active surveillance strategy). https:\/\/uroweb.org\/guidelines\/prostate-cancer. Accessed 26 Mar 2026"},{"issue":"3","key":"5634_CR28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.eururo.2020.03.035","volume":"78","author":"V Stavrinides","year":"2020","unstructured":"Stavrinides V, Giganti F, Trock B, et al (2020) Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 78(3):443\u2013451. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.035","journal-title":"Eur Urol"},{"issue":"2","key":"5634_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.eururo.2025.03.019","volume":"88","author":"C Englman","year":"2025","unstructured":"Englman C, Adebusoye B, Maffei D, et al (2025) Magnetic resonance imaging-led risk-adapted active surveillance for prostate cancer: updated results from a large cohort study. Eur Urol 88(2):167\u2013175. https:\/\/doi.org\/10.1016\/j.eururo.2025.03.019","journal-title":"Eur Urol"},{"issue":"5","key":"5634_CR30","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1007\/s00330-020-07336-0","volume":"31","author":"I Caglic","year":"2021","unstructured":"Caglic I, Sushentsev N, Gnanapragasam VJ, et al (2021) MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance. Eur Radiol 31(5):2696\u20132705. https:\/\/doi.org\/10.1007\/s00330-020-07336-0","journal-title":"Eur Radiol"},{"issue":"3","key":"5634_CR31","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1007\/s00330-020-07256-z","volume":"31","author":"F Giganti","year":"2021","unstructured":"Giganti F, Stavrinides V, Stabile A, et al (2021) Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort. Eur Radiol 31(3):1644\u20131655. https:\/\/doi.org\/10.1007\/s00330-020-07256-z","journal-title":"Eur Radiol"},{"issue":"4","key":"5634_CR32","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1007\/s00330-019-06557-2","volume":"30","author":"F Giganti","year":"2020","unstructured":"Giganti F, Pecoraro M, Stavrinides V, et al (2020) Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study. Eur Radiol 30(4):2082\u20132090. https:\/\/doi.org\/10.1007\/s00330-019-06557-2","journal-title":"Eur Radiol"},{"issue":"1116","key":"5634_CR33","doi-asserted-by":"publisher","first-page":"20200819","DOI":"10.1259\/bjr.20200819","volume":"93","author":"F Giganti","year":"2020","unstructured":"Giganti F, Stavrinides V, Stabile A, et al (2020) Prostate cancer measurements on serial MRI during active surveillance: it\u2019s time to be PRECISE. Br J Radiol 93(1116):20200819. https:\/\/doi.org\/10.1259\/bjr.20200819","journal-title":"Br J Radiol"},{"key":"5634_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-025-12318-1","author":"C Englman","year":"2026","unstructured":"Englman C, Adebusoye B, Cosenza M, et al (2026) Inter- and intra-rater variability of MRI-based lesion size measurements in active surveillance for prostate cancer: a multicentre study. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-025-12318-1","journal-title":"Eur Radiol"},{"issue":"3","key":"5634_CR35","doi-asserted-by":"publisher","first-page":"e242164","DOI":"10.1148\/radiol.242164","volume":"318","author":"F Giganti","year":"2026","unstructured":"Giganti F, Allen C, Dickinson L, Punwani S, Moore CM, Kirkham A (2026) MRI for Active Surveillance in Prostate Cancer: How I Do It. Radiology 318(3):e242164. https:\/\/doi.org\/10.1148\/radiol.242164","journal-title":"Radiology"},{"issue":"2","key":"5634_CR36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.eururo.2018.06.025","volume":"75","author":"L Klotz","year":"2019","unstructured":"Klotz L, Loblaw A, Sugar L, et al (2019) Active Surveillance Magnetic Resonance Imaging Study (ASIST): results of a randomized multicenter prospective trial. Eur Urol 75(2):300\u2013309. https:\/\/doi.org\/10.1016\/j.eururo.2018.06.025","journal-title":"Eur Urol"},{"issue":"4","key":"5634_CR37","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.clgc.2021.01.004","volume":"19","author":"P Pepe","year":"2021","unstructured":"Pepe P, Pepe L, Pennisi M, Fraggetta F (2021) Which prostate biopsy in men enrolled in active surveillance? Experience in 110 men submitted to scheduled three-years transperineal saturation biopsy combined with fusion targeted cores. Clin Genitourin Cancer 19(4):305\u2013308. https:\/\/doi.org\/10.1016\/j.clgc.2021.01.004","journal-title":"Clin Genitourin Cancer"},{"key":"5634_CR38","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/iju.15451","volume":"31","author":"M Kobayashi","year":"2024","unstructured":"Kobayashi M, Matsuoka Y, Uehara S, et al (2024) Utility of positive core number on MRI-ultrasound fusion targeted biopsy in combination with PI-RADS scores for predicting unexpected extracapsular extension of clinically localized prostate cancer. Int J Urol 31:739\u2013746. https:\/\/doi.org\/10.1111\/iju.15451","journal-title":"Int J Urol"},{"key":"5634_CR39","doi-asserted-by":"publisher","first-page":"111081","DOI":"10.1016\/j.urolonc.2026.111081","volume":"44","author":"M Kobayashi","year":"2026","unstructured":"Kobayashi M, Matsuoka Y, Kimura K, et al (2026) Diagnostic value of MRI-ultrasound fusion-targeted prostate biopsy for non-index lesions combined with the index lesion biopsy. Urol Oncol 44:111081. https:\/\/doi.org\/10.1016\/j.urolonc.2026.111081","journal-title":"Urol Oncol"},{"issue":"6","key":"5634_CR40","doi-asserted-by":"publisher","first-page":"e684-e687","DOI":"10.1016\/j.clgc.2020.04.001","volume":"18","author":"P Pepe","year":"2020","unstructured":"Pepe P, Pennisi M (2020) Negative biopsy histology in men with PI-RADS score 5 in daily clinical practice: incidence of granulomatous prostatitis. Clin Genitourin Cancer 18(6):e684-e687. https:\/\/doi.org\/10.1016\/j.clgc.2020.04.001","journal-title":"Clin Genitourin Cancer"},{"key":"5634_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.mri.2019.12.007","volume":"67","author":"F Giganti","year":"2020","unstructured":"Giganti F, Stabile A, Stavrinides V, et al (2020) DWI and PRECISE criteria in men on active surveillance for prostate cancer: a multicentre preliminary experience of different ADC calculations. Magn Reson Imaging 67:50\u201358. https:\/\/doi.org\/10.1016\/j.mri.2019.12.007","journal-title":"Magn Reson Imaging"},{"issue":"12","key":"5634_CR42","doi-asserted-by":"publisher","first-page":"7698","DOI":"10.1007\/s00330-024-10869-3","volume":"34","author":"V Bozgo","year":"2024","unstructured":"Bozgo V, Roest C, van Oort I, et al (2024) Prostate MRI and artificial intelligence during active surveillance: should we jump on the bandwagon? Eur Radiol 34(12):7698\u20137704. https:\/\/doi.org\/10.1007\/s00330-024-10869-3","journal-title":"Eur Radiol"},{"key":"5634_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00330-022-09032-7","volume":"33","author":"C Roest","year":"2023","unstructured":"Roest C, Kwee TC, Saha A, et al (2023) AI-assisted biparametric MRI surveillance of prostate cancer: feasibility study. Eur Radiol 33:89\u201396. https:\/\/doi.org\/10.1007\/s00330-022-09032-7","journal-title":"Eur Radiol"},{"key":"5634_CR44","doi-asserted-by":"publisher","first-page":"1149056","DOI":"10.3389\/fmed.2023.1149056","volume":"10","author":"T DeSilvio","year":"2023","unstructured":"DeSilvio T, Antunes JT, Bera K, et al. (2023) Region-specific deep learning models for accurate segmentation of rectal structures on post-chemoradiation T2w MRI: a multi-institutional, multi-reader study. Front Med (Lausanne) 10:1149056. https:\/\/doi.org\/10.3389\/fmed.2023.1149056","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"5634_CR45","doi-asserted-by":"publisher","first-page":"e2515672","DOI":"10.1001\/jamanetworkopen.2025.15672","volume":"8","author":"JJ Twilt","year":"2025","unstructured":"Twilt JJ, Saha A, Bosma JS, et al; PI-CAI Consortium (2025) AI-Assisted vs Unassisted Identification of Prostate Cancer in Magnetic Resonance Images. JAMA Netw Open 8(6):e2515672. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.15672","journal-title":"JAMA Netw Open"},{"issue":"3","key":"5634_CR46","doi-asserted-by":"publisher","first-page":"e210064","DOI":"10.1148\/ryai.210064","volume":"4","author":"AC Yu","year":"2022","unstructured":"Yu AC, Mohajer B, Eng J (2022) External validation of deep learning algorithms for radiologic diagnosis: a systematic review. Radiol Artif Intell 4(3):e210064. https:\/\/doi.org\/10.1148\/ryai.210064","journal-title":"Radiol Artif Intell"},{"key":"5634_CR47","doi-asserted-by":"publisher","first-page":"n2281","DOI":"10.1136\/bmj.n2281","volume":"375","author":"CL Andaur Navarro","year":"2021","unstructured":"Andaur Navarro CL, Damen JAA, Takada T, et al (2021) Risk of bias in studies on prediction models developed using supervised machine learning techniques: systematic review. BMJ 375:n2281. https:\/\/doi.org\/10.1136\/bmj.n2281","journal-title":"BMJ"},{"issue":"3","key":"5634_CR48","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1056\/NEJMc2104626","volume":"385","author":"SG Finlayson","year":"2021","unstructured":"Finlayson SG, Subbaswamy A, Singh K, et al (2021) The clinician and dataset shift in artificial intelligence. N Engl J Med 385(3):283\u2013286. https:\/\/doi.org\/10.1056\/NEJMc2104626","journal-title":"N Engl J Med"},{"issue":"2","key":"5634_CR49","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4081\/aiua.2021.2.139","volume":"93","author":"P Pepe","year":"2021","unstructured":"Pepe P, Garufi A, Priolo G, et al (2021) mpMRI PI-RADS score 3 lesions diagnosed by reference vs affiliated radiological centers: our experience in 950 cases. Arch Ital Urol Androl 93(2):139\u2013142. https:\/\/doi.org\/10.4081\/aiua.2021.2.139","journal-title":"Arch Ital Urol Androl"},{"issue":"1","key":"5634_CR50","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s00330-021-08151-x","volume":"32","author":"N Sushentsev","year":"2022","unstructured":"Sushentsev N, Rundo L, Blyuss O, et al (2022) Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance. Eur Radiol 32(1):680\u2013689. https:\/\/doi.org\/10.1007\/s00330-021-08151-x","journal-title":"Eur Radiol"},{"key":"5634_CR51","doi-asserted-by":"publisher","first-page":"12917","DOI":"10.1038\/s41598-021-92341-6","volume":"11","author":"N Sushentsev","year":"2021","unstructured":"Sushentsev N, Caglic I, Shaida N, et al (2021) MRI-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance. Sci Rep 11:12917. https:\/\/doi.org\/10.1038\/s41598-021-92341-6","journal-title":"Sci Rep"},{"key":"5634_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41571-022-00707-0","volume":"20","author":"EP Huang","year":"2023","unstructured":"Huang EP, O\u2019Connor JPB, McShane LM, et al (2023) Criteria for the translation of radiomics into clinically useful tests. Nat Rev Clin Oncol 20:69\u201382. https:\/\/doi.org\/10.1038\/s41571-022-00707-0","journal-title":"Nat Rev Clin Oncol"},{"key":"5634_CR53","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, Leijenaar RTH, Deist TM, et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14:749\u2013762. https:\/\/doi.org\/10.1038\/nrclinonc.2017.141","journal-title":"Nat Rev Clin Oncol"},{"key":"5634_CR54","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s00261-021-02954-8","volume":"46","author":"S Chen","year":"2021","unstructured":"Chen S, Ren S, Guo K, Daniels MJ, Wang Z, Chen R (2021) Preoperative differentiation of serous cystic neoplasms from mucin-producing pancreatic cystic neoplasms using a CT-based radiomics nomogram. Abdom Radiol 46:2637\u20132646. https:\/\/doi.org\/10.1007\/s00261-021-02954-8","journal-title":"Abdom Radiol"},{"key":"5634_CR55","doi-asserted-by":"publisher","first-page":"109373","DOI":"10.4329\/wjr.v17.i8.109373","volume":"17","author":"S Ren","year":"2025","unstructured":"Ren S, Qin B, Daniels MJ, Zeng L, Tian Y, Wang ZQ (2025) Developing and validating a computed tomography radiomics strategy to predict lymph node metastasis in pancreatic cancer. World J Radiol 17:109373. https:\/\/doi.org\/10.4329\/wjr.v17.i8.109373","journal-title":"World J Radiol"},{"key":"5634_CR56","doi-asserted-by":"publisher","first-page":"8027","DOI":"10.7150\/thno.61207","volume":"11","author":"SKB Spohn","year":"2021","unstructured":"Spohn SKB, Bettermann AS, Bamberg F, et al (2021) Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studies. Theranostics 11:8027\u20138042. https:\/\/doi.org\/10.7150\/thno.61207","journal-title":"Theranostics"},{"key":"5634_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-025-12248-y","author":"H Smith","year":"2026","unstructured":"Smith H, Stavrinides V, Giganti F, et al (2026) Variation in prostate cancer growth rates in an MRI-based active surveillance cohort. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-025-12248-y","journal-title":"Eur Radiol"},{"issue":"6","key":"5634_CR58","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1007\/s00330-023-09438-x","volume":"33","author":"N Sushentsev","year":"2023","unstructured":"Sushentsev N, Rundo L, Abrego L, et al (2023) Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance. Eur Radiol 33(6):3792\u20133800. https:\/\/doi.org\/10.1007\/s00330-023-09438-x","journal-title":"Eur Radiol"},{"key":"5634_CR59","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1093\/jamia\/ocad168","volume":"30","author":"LA Carrasco-Ribelles","year":"2023","unstructured":"Carrasco-Ribelles LA, Llanes-Jurado J, Gallego-Moll C, et al (2023) Prediction models using artificial intelligence and longitudinal data from electronic health records: a systematic methodological review. J Am Med Inform Assoc 30:2072\u20132082. https:\/\/doi.org\/10.1093\/jamia\/ocad168","journal-title":"J Am Med Inform Assoc"},{"key":"5634_CR60","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1111\/iju.15581","volume":"31","author":"K Shimada","year":"2024","unstructured":"Shimada K, Fujiwara M, Hirahara D, et al (2024) Monitoring prostate cancer after low-dose-rate hemigland brachytherapy with delta-radiomics of diffusion-weighted magnetic resonance imaging. Int J Urol 31:1443\u20131445. https:\/\/doi.org\/10.1111\/iju.15581","journal-title":"Int J Urol"},{"issue":"2","key":"5634_CR61","doi-asserted-by":"publisher","first-page":"13746","DOI":"10.4081\/aiua.2025.13746","volume":"97","author":"P Pepe","year":"2025","unstructured":"Pepe P, Pepe L, Cignoli D, Roscigno M (2025) PSMA PET\/CT in the diagnosis of prostate cancer: why and when? Arch Ital Urol Androl 97(2):13746. https:\/\/doi.org\/10.4081\/aiua.2025.13746","journal-title":"Arch Ital Urol Androl"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05634-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-026-05634-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05634-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:57:06Z","timestamp":1784350626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-026-05634-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":61,"alternative-id":["5634"],"URL":"https:\/\/doi.org\/10.1007\/s00261-026-05634-7","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author name in graphical abstract was changed from \u201cArita et al.\u201d to \u201cFujiwara et al\".","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As Y.A. is a Guest Editor of this collection, the entire peer-review and decision-making process was managed independently by other editorial board members. FG reports consulting fees from DeepHealth, SpectraCure and Procept outside of the submitted work. He has received speaker fees from Bayer and Siemens.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}